InvestorsHub Logo

H2R

Followers 42
Posts 2147
Boards Moderated 0
Alias Born 07/17/2014

H2R

Re: None

Thursday, 02/16/2017 5:14:10 PM

Thursday, February 16, 2017 5:14:10 PM

Post# of 1569
Expect results from VITALITY-ALS in Q4 2017.

Restating the pipeline status as part of the CC today:
http://seekingalpha.com/pr/16745540-cytokinetics-inc-reports-fourth-quarter-2016-financial-results


Skeletal Muscle Program
Tirasemtiv

Expect results from VITALITY-ALS in Q4 2017.

Expect to continue to enroll patients who complete VITALITY-ALS into VIGOR-ALS, an open-label extension trial throughout 2017.
CK-2127107

Expect data from a Phase 2 clinical trial of CK-2127107 in patients with SMA in 2H 2017.

Expect Astellas to continue enrollment in a Phase 2 clinical trial of CK-2127107 in patients with COPD in 2017.

Expect Astellas to begin a Phase 1b clinical trial of CK-2127107 in elderly patients with limited mobility in 1H 2017.

Expect to begin a Phase 2 clinical trial of CK-2127107 in patients with ALS in mid-2017.
Cardiac Muscle Program

omecamtiv mecarbil

Expect to continue to enroll patients with chronic heart failure in GALACTIC-HF, our Phase 3 clinical trial of omecamtiv mecarbil, throughout 2017.

Expect data from a Phase 2 clinical trial of omecamtiv mecarbil in Japanese patients with chronic heart failure in Q3 2017.
Pre-Clinical Research

Expect to continue research activities under our joint research program with Amgen directed to the discovery of next-generation cardiac muscle activators and under our joint research program with Astellas directed to the discovery of next-generation skeletal muscle activators.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYTK News